MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation
Cannabis Law Report
OCTOBER 26, 2021
MyMD’s lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid arthritis. MyMD’s lead drug candidate, MYMD-1, is being developed to target aging, aging-related diseases, and autoimmune diseases including rheumatoid arthritis. MyMD Pharmaceuticals, Inc.
Let's personalize your content